Tilapia Gut Bacteria Yield New Antibacterial Protein
The identified protein displays activity against common pathogens, offering a potential path to reduce aquaculture antibiotics.
Updated on Oct. 23, 2026 in Life Sciences
Researchers identified a potential new source of antimicrobial compounds within the gut microbiome of tilapia. The team isolated a protein from the bacterium Enterobacter ludwigii that demonstrates inhibitory activity against pathogens like Listeria monocytogenes.
Why it matters
Identifying bioactive compounds from aquaculture-associated bacteria provides a pathway to reduce the agricultural sector's reliance on conventional antibiotics. This research marks an early-stage exploration into sustainable alternatives for managing bacterial infections in fish populations.
The active fraction, derived from Enterobacter ludwigii isolate A1, contains a 162-amino-acid colicin V-like protein that demonstrated measurable inhibitory activity. The bacterium features a 4.96-Mb draft genome with a 54.31% GC content.
The players
Enterobacter ludwigii
A species of gram-negative, facultatively anaerobic bacteria often found in diverse environments including plant surfaces, water, and animal intestines.
Listeria monocytogenes
A foodborne bacterial pathogen that serves as a common benchmark for measuring the efficacy of novel antimicrobial compounds.
The details
Researchers screened 64 bacterial isolates from healthy tilapia before identifying isolate A1, which produced an active supernatant. They enriched this fraction using ammonium sulfate precipitation—a technique that uses salt to concentrate proteins—and dialysis. Proteinase K and trypsin treatment completely abolished the inhibitory effect, confirming the active component is a protein. The genome assembly was constructed from 61 contigs, revealing a colicin V-like domain, a type of pore-forming toxin used by bacteria to compete with other microbes.
Timeline
October 23, 2026: Research article published.
The Tech Race
This research follows a broader industry push to meet global aquaculture antibiotic reduction initiatives by finding biological alternatives to synthetic drugs. It adds to a growing catalog of microbial-derived antimicrobials intended to combat drug-resistant pathogens in food systems.
This discovery is in the research stage and does not impact current aquaculture practices or consumer food safety. Further studies are required to assess whether this protein can be scaled for commercial use in fish feed or health supplements.
The takeaway
The discovery of a colicin V-like protein in tilapia gut bacteria suggests a potential new tool for antimicrobial research in aquaculture. Interested researchers should monitor future studies for in vivo trials that test the protein's ability to inhibit pathogens within live fish populations.
Further reading
Explore more developments in the Life Sciences section.
Source note: This article includes information reported by Nature.
